European Venous Registry

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06906250

Acronym

EVeR

Enrollment

100

Registered

2025-04-02

Start date

2025-07-05

Completion date

2034-09-30

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep Venous Disease of the Lower Limbs

Keywords

acute or chronic lower limb deep venous disease, iliac and/or common femoral veins, inferior vena cava

Brief summary

The European Venous Registry (EVeR) is an international repository of data on the treatments and outcomes of people with deep venous disease. The registry is designed to evaluate the outcomes of venous interventions over a ten-year period, with the ultimate goal to inform clinical decision making through the delivery of scientific evidence.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with an imaging-confirmed new diagnosis of acute or chronic lower limb deep venous disease involving the iliac and/or common femoral veins, with or without extension to the inferior vena cava, or patients with an imaging-confirmed new diagnosis involving the IVC only. * Consent to enter registry.

Exclusion criteria

* Unable to consent to enter into registry. * Isolated upper limb DVT. * Central venous thrombosis (e.g. superior vena cava obstruction). * Isolated deep vein thrombosis below the common femoral vein. * Isolated superficial venous thrombosis. * Isolated superficial venous thrombophlebitis. * Isolated varicose veins. * Aged \<18 years.

Design outcomes

Primary

Measure	Time frame	Description
Clinical Severity Scores	end of the procedure	Difference of Clinical efficacy will be evaluated using the Villalta score (range 0-33). The patient was diagnosed as having Post-thrombotic syndrome if the Villalta score was ≥5 or if a venous ulcer was present. A score of 5-9 signifies mild disease, 10-14 moderate disease, and ≥15 severe disease.

Secondary

Measure	Time frame	Description
Venous Insufficiency Epidemiological and Economic Study/Quality of Life (VEINES-QOL)	10 years	Improvement of quality of life will be evaluated using the Veines - qol score.The VEINES-QOL questionnaire consists of 26 items. Each question is standardised using the mean and standard deviation of the sample being coded to give a z-score, these are averaged, and the result transformed to T-scores (mean = 50; standard deviation = 10). High values indicate better outcomes.

Countries

France, Germany, Greece, Ireland, Italy, Netherlands, Spain, Turkey (Türkiye), United Kingdom

Outcome results